Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

Cited by (1,093)

Items 501–600 of 1,093

1. Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study–Renal ( <scp>CANVAS‐R</scp> ): A randomized, placebo‐controlled trial
   Neal, Bruce, Perkovic, Vlado, Matthews, David R., Mahaffey, Kenneth W., Fulcher, Greg, Meininger, Gary, Erondu, Ngozi, Desai, Mehul, Shaw, Wayne, Vercruysse, Frank et al. · 2017 · Diabetes, Obesity and Metabolism
2. Clinical Application of Incretin-Based Therapy: Therapeutic Potential, Patient Selection and Clinical Use
   David M. Kendall, Robert M Cuddihy, Richard M. Bergenstal · 2009 · The American Journal of Medicine
3. Hypoglycemia is more common among type 2 diabetes patients with limited health literacy: The Diabetes Study of Northern California (DISTANCE)
   Sarkar, Urmimala, Karter, Andrew J., Liu, Jennifer Y., Moffet, Howard H., Adler, Nancy E., Schillinger, Dean · 2010 · Journal of General Internal Medicine
4. Sex differences in type 2 diabetes: focus on disease course and outcomes
   Arnetz, Lisa, Rajamand Ekberg, Neda, Alvarsson, Michael · 2014 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
5. Insulin therapy and hypoglycemia
   McCall, Anthony L. · 2012 · Endocrinology and Metabolism Clinics of North America
6. Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis
   Christian Sonesson, Peter A. Johansson, EVA K. JOHNSSON, Ingrid A. M. Gause‐Nilsson · 2016 · Cardiovascular Diabetology
7. Lipid Management in Patients with Endocrine Disorders: An Endocrine Society Clinical Practice Guideline
   Connie B. Newman, Michael Joseph Blaha, Jeffrey B. Boord, Bertrand Cariou, Alan Chait, Henry G. Fein, Henry N. Ginsberg, Ira J. Goldberg, Mohammad Hassan Murad, Savitha Subramanian et al. · 2020 · The Journal of Clinical Endocrinology & Metabolism
8. Effects of Long-term Metformin and Lifestyle Interventions on Cardiovascular Events in the Diabetes Prevention Program and Its Outcome Study
   Ronald B Goldberg, Trevor John Orchard, Jill P. Crandall, Edward J. Boyko, Matthew Jay Budoff, Dana Dabelea, Kishore M. Gadde, William C. Knowler, Christine G. Lee, David M. Nathan et al. · 2022 · Circulation
9. Treatment of chronic kidney disease
   Jeffrey M. Turner, Carolyn A. Bauer, Matthew K. Abramowitz, Michal L. Melamed, Thomas H. Hostetter · 2011 · Kidney International
10. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease
    Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John Dean Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan A. Fowler, Gary H. Friday et al. · 2011 · Stroke
11. Relationship between hypoglycemic episodes and ventricular arrhythmias in patients with type 2 diabetes and cardiovascular diseases: silent hypoglycemias and silent arrhythmias
    Stahn, Annett, Pistrosch, Frank, Ganz, Xenia, Teige, Madlen, Koehler, Carsta, Bornstein, Stefan, Hanefeld, Markolf · 2014 · Diabetes Care
12. Intensive glycemic control and cardiovascular disease: an update
    Aparna Brown, L. Raymond Reynolds, Dennis Bruemmer · 2010 · Nature Reviews Cardiology
13. Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes
    Jin Joo Park · 2021 · Diabetes & Metabolism Journal
14. GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data
    Sposito, Andrei C., Berwanger, Otávio, de Carvalho, Luiz Sérgio F., Saraiva, José Francisco Kerr · 2018 · Cardiovascular Diabetology
15. Coronary Artery Disease and Type 2 Diabetes Mellitus
    Ryo Naito, Katsumi Miyauchi · 2017 · International Heart Journal
16. Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy
    Mohammad Shamsul Ola, Mohd Imtiaz Nawaz, Mohammad Mairaj Siddiquei, Saleh A. Al-Amro, Ahmed M. Abu El‐Asrar · 2012 · Journal of Diabetes and its Complications
17. Interactions between kidney disease and diabetes: dangerous liaisons
    Roberto Pecoits‐Filho, Hugo Abensur, Carolina de Castro Rocha Betônico, Alisson Diego Machado, Erika Bezerra Parente, Márcia Silva Queiroz, João Eduardo Nunes Salles, Silvia Titan, Sérgio Alberto Cunha Vencio · 2016 · Diabetology & Metabolic Syndrome
18. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study
    Drury, P. L., Ting, R., Zannino, D., Ehnholm, C., Flack, J., Whiting, M., Fassett, R., Ansquer, J.-C., Dixon, P., Davis, T. M. E. et al. · 2011 · Diabetologia
19. Comorbidity Affects the Relationship Between Glycemic Control and Cardiovascular Outcomes in Diabetes
    Sheldon Greenfield, John Billimek, Fabio Pellegrini, Monica Franciosi, Giorgia De Berardis, Antonio Nicolucci, Sherrie H. Kaplan · 2009 · Annals of Internal Medicine
20. Therapeutic approaches to diabetic nephropathy—beyond the RAS
    Beatriz Fernández‐Fernández, Alberto Ortíz, Carmen Gómez‐Guerrero, Jesús Egido · 2014 · Nature Reviews Nephrology
21. Mechanisms of Vascular Disease: A Reference Book for Vascular Specialists
    Robert Fitridge, Matthew M. Thompson · 2011
22. Importance of cardiovascular disease risk management in patients with type 2 diabetes mellitus
    Daniel Lorber · 2014 · Diabetes Metabolic Syndrome and Obesity
23. Randomized Controlled Trial of Clinical Pharmacy Management of Patients with Type 2 Diabetes in an Outpatient Diabetes Clinic in Jordan
    Anan S. Jarab, S Alqudah, Tareq Lewis Mukattash, Ghassan F. Shattat, Tariq Musbah Al‐Qirim · 2012 · Journal of Managed Care Pharmacy
24. Hydrolyzed Infant Formula and Early β-Cell Autoimmunity
    M. Knip, H. Akerblom, D. Becker, H. Dosch, J. Dupré, W. Fraser, N. Howard, J. Ilonen, J. Krischer, O. Kordonouri et al. · 2014 · Journal of the American Medical Association (JAMA)
25. Revisiting the links between glycaemia, diabetes and cardiovascular disease
    Sattar, N. · 2013 · Diabetologia
26. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts)
    F. Piepoli, Massimo · 2017 · International Journal of Behavioral Medicine
27. Soluble forms of RAGE in internal medicine
    Natale Vazzana, Francesca Santilli, Chiara Cuccurullo, Giovanni Davı̀ · 2009 · Internal and Emergency Medicine
28. Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus
    Muhammad A Abdul‐Ghani, Luke Norton, Ralph Anthony DeFronzo · 2015 · American Journal of Physiology-Renal Physiology
29. Sodium-glucose cotransporter-2 inhibition for the reduction of cardiovascular events in high-risk patients with diabetes mellitus
    Nikolaus Marx, Darren K. McGuire · 2016 · European Heart Journal
30. Sulfonylureas: A New Look at Old Therapy
    Peter M. Thulé, Guillermo E. Umpierrez · 2014 · Current Diabetes Reports
31. Advances in the Treatment of Type 2 Diabetes Mellitus
    Zafar H. Israili · 2010 · American Journal of Therapeutics
32. Vitamin B12 Supplementation in Diabetic Neuropathy: A 1-Year, Randomized, Double-Blind, Placebo-Controlled Trial
    Triantafyllos Didangelos, Eleni Karlafti, Evangelia Kotzakioulafi, Eleni Margariti, Parthena Giannoulaki, Georgios Batanis, Solomon Hailemariam Tesfaye, Kοnstantinos Kantartzis · 2021 · Nutrients
33. Results of a Successful Telephonic Intervention to Improve Diabetes Control in Urban Adults
    Elizabeth A. Walker, Celia Shmukler, Ralph Ullman, Emelinda Blanco, Melissa Scollan‐Koliopoulos, Hillel W. Cohen · 2010 · Diabetes Care
34. Circulating Inflammatory Markers and the Risk of Vascular Complications and Mortality in People With Type 2 Diabetes and Cardiovascular Disease or Risk Factors: The ADVANCE Study
    Gordon D O Lowe, Mark Woodward, Graham S. Hillis, Ann Rumley, Qiang Li, Stephen B. Harrap, Michel Marre, Pavel Hamet, Anushka A Patel, Neil R Poulter et al. · 2013 · Diabetes
35. Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging
    Yuanbing Jiang, Xiaopu Zhou, Fanny C.F. Ip, Philip Chan, Yu Chen, Nicole Chit Hang Lai, Kit Cheung, Ronnie M.N. Lo, Estella P.S. Tong, Bonnie W.Y. Wong et al. · 2021 · Alzheimer s & Dementia
36. Heart failure: epidemiology and prevention in India.
    Mark D. Huffman, Dorairaj Prabhakaran · 2010 · PubMed
37. Omega-3 polyunsaturated fatty acids favourably modulate cardiometabolic biomarkers in type 2 diabetes: a meta-analysis and meta-regression of randomized controlled trials
    O’Mahoney, Lauren L., Matu, Jamie, Price, Oliver J., Birch, Karen M., Ajjan, Ramzi A., Farrar, Diane, Tapp, Robyn, West, Daniel J., Deighton, Kevin, Campbell, Matthew D. · 2018 · Cardiovascular Diabetology
38. Assessing the cardio–cerebrovascular safety of vildagliptin: meta‐analysis of adjudicated events from a large Phase III type 2 diabetes population
    Anja Schweizer, Sylvie Dejager, James Edward Foley, A. Couturier, Monica Ligueros‐Saylan, Wolfgang Kothny · 2010 · Diabetes Obesity and Metabolism
39. Results of a reevaluation of cardiovascular outcomes in the RECORD trial
    Kenneth W. Mahaffey, Gail E. Hafley, Sheila Dickerson, Shana Burns, Sandra Tourt-Uhlig, Jennifer A. White, Laura Kristin Newby, Michel Komajda N, John J.V. McMurray, Robert Bigelow et al. · 2013 · American Heart Journal
40. 2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS Guideline on the Management of Patients With Extracranial Carotid and Vertebral Artery Disease: Executive Summary
    Thomas G. Brott, Jonathan L. Halperin, Suhny Abbara, J. Michael Bacharach, John Dean Barr, Ruth L. Bush, Christopher U. Cates, Mark A. Creager, Susan A. Fowler, Gary H. Friday et al. · 2011 · Stroke
41. Hypoglycemia, Diabetes, and Cardiovascular Disease
    Janet K. Snell‐Bergeon, Raj Paul Wadwa · 2012 · Diabetes Technology & Therapeutics
42. Metabolic memory: mechanisms and diseases
    Hao Dong, Yuezhang Sun, Lulingxiao Nie, Aimin Cui, Pengfei Zhao, Wai Keung Leung, Qi Wang · 2024 · Signal Transduction and Targeted Therapy
43. Effect of Intensive Compared With Standard Glycemia Treatment Strategies on Mortality by Baseline Subgroup Characteristics
    Calles-Escandón, Jorge, Lovato, Laura C., Simons-Morton, Denise G., Kendall, David M., Pop-Busui, Rodica, Cohen, Robert M., Bonds, Denise E., Fonseca, Vivian A., Ismail-Beigi, Faramarz, Banerji, Mary Ann et al. · 2010 · Diabetes Care
44. Meta-analysis of studies examining medication adherence, persistence, and discontinuation of oral antihyperglycemic agents in type 2 diabetes
    Iglay, Kristy, Cartier, Shannon E., Rosen, Virginia M., Zarotsky, Victoria, Rajpathak, Swapnil N., Radican, Larry, Tunceli, Kaan · 2015 · Current Medical Research and Opinion
45. Metabolic memory phenomenon in diabetes mellitus: Achieving and perspectives
    Alexander Е. Berezin · 2016 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
46. Event rates, hospital utilization, and costs associated with major complications of diabetes: a multicountry comparative analysis
    Clarke, Philip M., Glasziou, Paul, Patel, Anushka, Chalmers, John, Woodward, Mark, Harrap, Stephen B., Salomon, Joshua A., on behalf of the ADVANCE Collaborative Group · 2010 · PLoS Medicine
47. Glycemic Control in Type 2 Diabetes: Time for an Evidence-Based About-Face?
    Víctor M. Montori, Mercè Fernández-Balsells · 2009 · Annals of Internal Medicine
48. Effects of β-blockers on glucose and lipid metabolism
    Vivian Andrew Fonseca · 2010 · Current Medical Research and Opinion
49. Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
    Juan Camilo Arjona Ferreira, Michel Marre, Nir Barzilai, Hua Guo, Gregory T. Golm, Christine McCrary Sisk, Keith D. Kaufman, Barry J. Goldstein · 2012 · Diabetes Care
50. Diabetes and its comorbidities—where East meets West
    Alice P.S. Kong, Gang Xu, Nicola Brown, Wing‐Yee So, Ronald C.W., Juliana C.N. Chan · 2013 · Nature Reviews Endocrinology
51. Ten Emerging Trends in the Epidemiology of Diabetic Retinopathy
    Charumathi Sabanayagam, Wanfen Yip, Daniel Shu Wei Ting, Gavin Siew Wei Tan, Tien Yin Wong · 2016 · Ophthalmic Epidemiology
52. Glucose-lowering drugs or strategies, atherosclerotic cardiovascular events, and heart failure in people with or at risk of type 2 diabetes: an updated systematic review and meta-analysis of randomised cardiovascular outcome trials
    Ghosh-Swaby, Olivia R, Goodman, Shaun G, Leiter, Lawrence A, Cheng, Alice, Connelly, Kim A, Fitchett, David, Jüni, Peter, Farkouh, Michael E, Udell, Jacob A · 2020 · The Lancet Diabetes &amp; Endocrinology
53. Severe Hypoglycemia Predicts Mortality in Diabetes
    Philip E. Cryer · 2012 · Diabetes Care
54. Prestroke Glycemic Control Is Associated With the Functional Outcome in Acute Ischemic Stroke
    Masahiro Kamouchi, Takayuki Matsuki, Jun Hata, Takahiro Kuwashiro, Tetsuro Ago, Yoshiki Sambongi, Yoshihisa Fukushima, Hiroshi Sugimori, Takanari Kitazono, for the FSR Investigators · 2011 · Stroke
55. Glycemic variability in the development of cardiovascular complications in diabetes
    Annunziata Nusca, Dario Tuccinardi, Marzia Albano, Camilla Cavallaro, Elisabetta Ricottini, Silvia Manfrini, Paolo Pozzilli, Germano Di Sciascio · 2018 · Diabetes/Metabolism Research and Reviews
56. Hypoglycemia in diabetes: An update on pathophysiology, treatment, and prevention
    Afif Nakhleh, Naim Shehadeh · 2021 · World Journal of Diabetes
57. Diabetic cardiomyopathy
    Omar Asghar, Ahmed Abdulrahman Alsunni, Kaivan Khavandi, Ali Khavandi, Sarah Withers, Adam S. Greenstein, Anthony Michael Heagerty, Rayaz Ahmed Malik · 2009 · Clinical Science
58. Guideline recommendations and the positioning of newer drugs in type 2 diabetes care
    Nikolaus Marx, Melanie Jane Davies, Peter J. Grant, Chantal Mathieu, John R. Petrie, Francesco Cosentino, John B. Buse · 2020 · The Lancet Diabetes & Endocrinology
59. Benefits and harms of intensive glycemic control in patients with type 2 diabetes
    Rodriguez-Gutierrez, René, Gonzalez-Gonzalez, José Gerardo, Zuñiga-Hernandez, Jorge A, McCoy, Rozalina G · 2019 · BMJ
60. Updates on the Management of Diabetes in Dialysis Patients
    Connie M. Rhee, Angela M. Leung, Csaba Pal Kovesdy, Katherine E. Lynch, Gregory A. Brent, Kamyar Kalantar‐Zadeh · 2014 · Seminars in Dialysis
61. Relationship of Insulin Resistance and Related Metabolic Variables to Coronary Artery Disease: A Mathematical Analysis
    David M. Eddy, Len Schlessinger, Richard Kahn, Barbara Peskin, RICK J. SCHIEBINGER · 2008 · Diabetes Care
62. Cardiac Autonomic Neuropathy in Diabetes: A Predictor of Cardiometabolic Events
    Aaron I. Vinik, CAROLINA M. CASELLINI, Henri K. Parson, Sheri R. Colberg, Marie-Laure Névoret · 2018 · Frontiers in Neuroscience
63. The extra‐pancreatic effects of <scp>GLP‐1</scp> receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems
    Seufert, J., Gallwitz, B. · 2014 · Diabetes, Obesity and Metabolism
64. Glycemic variability and cardiovascular disease in patients with type 2 diabetes
    Martinez, Marcela, Santamarina, Jimena, Pavesi, Adrian, Musso, Carla, Umpierrez, Guillermo E · 2021 · BMJ Open Diabetes Research &amp; Care
65. Management of diabetic nephropathy: Recent progress and future perspective
    Jamal Ahmad · 2015 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
66. Breaking down patient and physician barriers to optimize glycemic control in type 2 diabetes.
    S. Ross · 2013 · American Journal of Medicine
67. Effects of Aggressive Versus Moderate Glycemic Control on Clinical Outcomes in Diabetic Coronary Artery Bypass Graft Patients
    Harold L. Lazar, Marie Elizabeth McDonnell, Stuart R. Chipkin, Carmel A. Fitzgerald, Caleb A. Bliss, Howard Cabral · 2011 · Annals of Surgery
68. Hypertension with diabetes mellitus complications
    Daisuke Yamazaki, Hirofumi Hitomi, Akira Nishiyama · 2018 · Hypertension Research
69. Diabetes and Arrhythmias: Pathophysiology, Mechanisms and Therapeutic Outcomes
    Laurel A. Grisanti · 2018 · Frontiers in Physiology
70. Evidence-based practice guideline for the treatment for diabetes in Japan 2013
    Tajima, Naoko, Noda, Mitsuhiko, Origasa, Hideki, Noto, Hiroshi, Yabe, Daisuke, Fujita, Yukihiro, Goto, Atsushi, Fujimoto, Kei, Sakamoto, Masaya, Haneda, Masakazu · 2015 · Diabetology International
71. Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia
    Khunti, Sachin, Khunti, Kamlesh, Seidu, Samuel · 2019 · Therapeutic Advances in Endocrinology and Metabolism
72. Sodium-Glucose Co-Transport Inhibitors
    Joshua J. Neumiller, John Raymond White, R. Keith Campbell · 2010 · Drugs
73. Effects of diabetes on myocardial infarct size and cardioprotection by preconditioning and postconditioning
    Takayuki Miki, Takahito Itoh, Daisuke Sunaga, Tetsuji Miura · 2012 · Cardiovascular Diabetology
74. The duration of diabetes affects the response to intensive glucose control in type 2 subjects: the VA Diabetes Trial
    Duckworth, William C., Abraira, Carlos, Moritz, Thomas E., Davis, Stephen N., Emanuele, Nicholas, Goldman, Steven, Hayward, Rodney, Huang, Grant D., Marks, Jennifer B., Reaven, Peter D. et al. · 2011 · Journal of Diabetes and its Complications
75. The Role of Mitochondria in the Pathophysiology of Skeletal Muscle Insulin Resistance
    Pagel-Langenickel, Ines, Bao, Jianjun, Pang, Liyan, Sack, Michael N. · 2010 · Endocrine Reviews
76. Insulin Therapy for Type 2 Diabetes Mellitus
    Amisha Wallia, Mark E. Molitch · 2014 · JAMA
77. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes
    Robert E. Ratner, Jenny Han, Dawn Nicewarner, Irina Yushmanova, Byron J. Hoogwerf, Larry Zaiqian Shen · 2011 · Cardiovascular Diabetology
78. Pharmacotherapy of type 2 diabetes: An update and future directions
    Antea J. DeMarsilis, Niyoti Reddy, Chrysoula Boutari, Andreas Filippaios, Elliot Sternthal, Niki Katsiki, Christos Socrates Mantzoros · 2022 · Metabolism
79. EXamination of CArdiovascular OutcoMes with AlogliptIN versus Standard of CarE in Patients with Type 2 Diabetes Mellitus and Acute Coronary Syndrome (EXAMINE)
    White, William B., Bakris, George L., Bergenstal, Richard M., Cannon, Christopher P., Cushman, William C., Fleck, Penny, Heller, Simon, Mehta, Cyrus, Nissen, Steven E., Perez, Alfonso et al. · 2011 · American Heart Journal
80. Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms
    Stephen J. Tonna, Assam El‐Osta, Mark Emmanuel Cooper, Chris Tikellis · 2010 · Nature Reviews Nephrology
81. The Effects of Dipeptidyl Peptidase-4 Inhibition on Microvascular Diabetes Complications
    Angelo Avogaro, Gian Paolo Fadini · 2014 · Diabetes Care
82. Dyslipidemia, Kidney Disease, and Cardiovascular Disease in Diabetic Patients
    Szu-chi Chen, Chin‐Hsiao Tseng · 2013 · The Review of Diabetic Studies
83. The relationship between bipolar disorder and type 2 diabetes: More than just co-morbid disorders
    Cynthia Calkin, David Martin Gardner, Thomas P. P. Ransom, Martin Alda · 2012 · Annals of Medicine
84. Comparison of waist-to-hip ratio and other obesity indices as predictors of cardiovascular disease risk in people with type-2 diabetes: a prospective cohort study from ADVANCE
    Sébastien Czernichow, André Pascal Kengne, Rachel Huxley, George David Batty, Bastiaan E. de Galan, Diederick E. Grobbee, Avinesh Pillai, Sophia Zoungas, Michel Marre, Mark Woodward et al. · 2010 · European Journal of Cardiovascular Prevention & Rehabilitation
85. Cardiovascular Risk Factor Targets and Cardiovascular Disease Event Risk in Diabetes: A Pooling Project of the Atherosclerosis Risk in Communities Study, Multi-Ethnic Study of Atherosclerosis, and Jackson Heart Study
    Nathan D. Wong, Yanglu Zhao, Rohini J. Patel, Christopher Patao, Shaista Malik, Alain Gerald Bertoni, Adolfo Correa, Aaron R. Folsom, Sumesh Kachroo, Jayanti Mukherjee et al. · 2016 · Diabetes Care
86. Vascular Cognitive Impairment and Dementia
    Ellen Chang Wong, Helena Chang Chui · 2022 · CONTINUUM Lifelong Learning in Neurology
87. Cardiovascular outcomes in type 1 and type 2 diabetes
    Annika Rosengren, Pigi Dikaiou · 2023 · Diabetologia
88. Guidelines and Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus
    David B. Sacks, Mark A. Arnold, George L. Bakris, David E. Bruns, Andrea Rita Horvath, Åke Lernmark, Boyd E. Metzger, David M. Nathan, Marian Sue Kirkman · 2023 · Clinical Chemistry
89. Dipeptidyl Peptidase‐4 Inhibitors for the Treatment of Type 2 Diabetes Mellitus
    Joshua J. Neumiller, Lindy D. Wood, R. Keith Campbell · 2010 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
90. Barriers to effective insulin treatment: the persistence of poor glycemic control in type 2 diabetes
    Stuart A. Ross, Hugh D. Tildesley, John Ashkenas · 2011 · Current Medical Research and Opinion
91. Intensified glucose lowering in type 2 diabetes: time for a reappraisal
    John S Yudkin, Bernd Richter, E. A. M. Gale · 2010 · Diabetologia
92. Changes in insulin sensitivity in response to different modalities of exercise: a review of the evidence
    S. Mann, Chris Beedie, Stefano Balducci, Silvano Zanuso, Judith E. Allgrove, Francesco Bertiato, Alfonso Jiménez · 2013 · Diabetes/Metabolism Research and Reviews
93. Empagliflozin Improves Left Ventricular Diastolic Dysfunction in a Genetic Model of Type 2 Diabetes
    Nadjib Hammoudi, Dongtak Jeong, Rajvir Singh, Ahmed Majid Farhat, Michel Komajda N, Eric Mayoux, Roger J. Hajjar, Djamel Lebeche · 2017 · Cardiovascular Drugs and Therapy
94. Antihypertensive agents for preventing diabetic kidney disease
    Jicheng Lv, Vlado Perkovic, Celine Foote, Maria E. Craig, Jonathan C. Craig, Giovanni FM Strippoli · 2012 · Cochrane Database of Systematic Reviews
95. Large-scale plasma lipidomic profiling identifies lipids that predict cardiovascular events in secondary prevention
    Piyushkumar A. Mundra, Christopher K. Barlow, Paul John Nestel, Elizabeth Helen Barnes, Adrienne C Kirby, Peter Lindsay Thompson, DAVID R. SULLIVAN, Zahir H. Alshehry, Natalie A. Mellett, Kevin Huynh et al. · 2018 · JCI Insight
96. Exenatide compared with long‐acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long‐Acting insulin (HEELA) study
    Melanie Jane Davies, Richard Donnelly, Anthony H Barnett, S. Jones, Claudia Nicolay, Aoife Kilcoyne · 2009 · Diabetes Obesity and Metabolism
97. Risk association of HbA1c variability with chronic kidney disease and cardiovascular disease in type 2 diabetes: prospective analysis of the Hong Kong Diabetes Registry
    Andrea O. Y. Luk, Ronald C.W., Eric S. H. Lau, Xilin Yang, Winnie W. Y. Lau, Linda W.L. Yu, Francis C. C. Chow, Juliana C.N. Chan, Wing‐Yee So · 2013 · Diabetes/Metabolism Research and Reviews
98. Systemic and renal lipids in kidney disease development and progression
    PATRICIA W. WAHL, Gloria Michelle Ducasa, Alessia Fornoni · 2015 · American Journal of Physiology-Renal Physiology
99. Gaps and barriers in the control of blood glucose in people with type 2 diabetes
    Lawrence Blonde, Pablo J. Aschner, Clifford J. Bailey, Linong Ji, Lawrence A. Leiter, Stephan Matthaei, on behalf of the Global Partnership for Effective Diabetes Management · 2017 · Diabetes and Vascular Disease Research
100. Deprescribing antihyperglycemic agents in older persons: Evidence-based clinical practice guideline.
     Barbara J. Farrell, Cody D. Black, Wade Thompson, Lisa M. McCarthy, Carlos H. Rojas‐Fernandez, Heather Anne Lochnan, Salima Shamji, Ross E. G. Upshur, Manon Bouchard, Vivian Andrea Welch · 2017 · Europe PMC (PubMed Central)